
Academic Emergency Physician. Director of Adult Research @columbiaEM. Syncope researcher. Views are my own and not my employer's.
Manhattan, NY
Joined April 2017
- Tweets1.4K
- Following312
- Followers932
- Likes8.8K
Pinned Tweet
Very pleased to share our publication validating the FAINT and Canadian Syncope Scores for ED patients with unexplained syncope in @JAMANetworkOpen
Both showed excellent discrimination.
The FAINT score outperformed physician gestalt w/r/t sensitivity.
jamanetwork.com/journals/jam…
Marc Probst, MD retweeted
Which ED patients with unexplained syncope need an Echo? ❤️🩹 There's a score for that: The ROMEO Score. Just validated in age 40+ . Now out in @AcademicEmerMed @probstMD
Read it here: onlinelibrary.wiley.com/doi/…
Which ED patients with unexplained syncope need an Echo? ❤️🩹
There's a score for that: The ROMEO Score. Just validated in age 40+ . Now out in @AcademicEmerMed
(Risk Of Major Echocardiography findings in Older adults with syncope)
Score below...
onlinelibrary.wiley.com/doi/…
Marc Probst, MD retweeted
We invented a new biomarker for cardiovascular disease. The New York Times tells our story (link in comments).
Marc Probst, MD retweeted
Both the Canadian Syncope Risk Score and FAINT score identified emergency department patients at low risk for serious outcomes, with FAINT showing higher sensitivity than physicians for serious cardiac outcomes.
ja.ma/499syAD
Elements of the FAINT score:
F - History of heart Failure (+1)
A - History of cardiac Arrhythmia (+1)
I - Initial abnormal ECG result (+1)
N - Elevated NT-proBNP (+2)
T - Elevated high-sensitivity Troponin (+1)
Marc Probst, MD retweeted
Congratulations to Dr. Chernick & Dr. Probst for their recent publication evaluating the efficacy of a digital patient decision aid, "STIckER" in increasing STI testing among adolescents and young adults in the ED!
Read more pubmed.ncbi.nlm.nih.gov/4213…
Marc Probst, MD retweeted
Congratulations to Drs. Dana Sacco, Ed Suh, and Marc Probst on their recent publication in @AnnalsofEM
examining sex-differences in clinical outcomes after syncope @probstMD
annemergmed.com/article/S019…
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis | @NEJM
nejm.org/doi/10.1056/NEJMoa2…
Marc Probst, MD retweeted
Congrats to Drs. Ed Suh, Dana Sacco and Marc Probst, on their recent publication in @AnnalsofEM comparing clinical management and outcomes among ED patients with syncope vs. presyncope @probstMD
Read it here: authors.elsevier.com/c/1lp-v…
Marc Probst, MD retweeted
This #StopTheStigmaEM event will examine the role of peer support in helping colleagues through complex realities and highlight tips for creating a culture where clinicians can speak openly about their struggles and receive meaningful support.
Register: ow.ly/SJH450WVgTf
Marc Probst, MD retweeted
Here's the best 60 second PSA illustrating what we do to children when we give them a smartphone. We ask them to do the impossible.
Join Smartphone Free Childhood!
youtube.com/watch?v=h_xwJ5u9…
Great to see NYP resident Eli Rogers presenting our work on validation of the Canadian Syncope Risk Score at #acep25
The score performed just as well for ED patients with presyncope as for those with syncope.
@ACEPNation @ColumbiaEM @NYEmergency
Among kids with AGE, ondansetron (Zofran) led to lower risk of moderate-to-severe gastroenteritis during the subsequent 7 days compared with placebo.
New RCT in @NEJM
nejm.org/doi/10.1056/NEJMoa2…
Marc Probst, MD retweeted
Come join our world-class team as we are recruiting for an Assistant Medical Director for the Pediatric Emergency Department at the NewYork-Presbyterian Children's Hospital of New York at Morgan Stanley in Manhattan and NewYork-Presbyterian Westchester in Bronxville! #pediatrics
Marc Probst, MD retweeted
Help us fill NIH study sections with #EmergencyMedicine investigators by nominating yourself or another expert by September 30! With more EM investigators, there will be more opportunities for #EmergencyCare investigators to succeed.
Learn more: ow.ly/1JX350WFzI4
Marc Probst, MD retweeted
A nasal spray reduced the risk of Covid infections in a double blind, placebo controlled randomized trial
jamanetwork.com/journals/jam…
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: Phase 2 RCT
▶️OTC Allergy spray reduction COVID infections by 70%👃
jamanetwork.com/journals/jam…
















